Document:

EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 

SECOND AMENDMENT TO LOAN AND SECURITY
AGREEMENT 
 THIS SECOND AMENDMENT TO LOAN
AND SECURITY AGREEMENT, dated as of January 22, 2016 (this “Amendment”), made by and between VIKING THERAPEUTICS,
INC., a Delaware corporation (“Borrower”), and LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation ( “Lender”), amends
the terms of the Loan and Security Agreement, dated May 21, 2014, as amended on April 8, 2015, by and between Borrower and Lender (the “Agreement”) pursuant to Section 25(c) of the Agreement as follows: 

1. Definitions. 
 (a) The
definition of “Borrower Equity” in Schedule A to the Agreement is amended and restated to read in its entirety as follows: 

““Borrower Equity” means: (i) with respect to the Next Financing, the New Preferred, Common Stock and/or other
equity securities of Borrower to be issued by Borrower in the Next Financing, or (ii) with respect to any prepayment made pursuant to Section 2(e)(i) through the issuance of securities of Borrower, Common Stock.” 

(b) The definition of “Borrower Securities” in Schedule A to the Agreement is amended and restated to read in its entirety as
follows: 
 ““Borrower Securities” means the Borrower Equity Securities.” 

(c) The definition of “Maturity Date” in Schedule A to the Agreement is amended and restated to read in its entirety as follows:

 ““Maturity Date” means May 21, 2017.” 

(d) The following definition is hereby added to Schedule A: 

““Common Stock” means Borrower’s common stock, par value $0.00001 per share.” 

2. Conversion, Prepayment. Section 2(c) of the Agreement shall be amended and restated to read in its entirety as follows: 

“(c) Conversion of Loans Upon Next Financing. 

(i) Upon the consummation of the first bona fide capital financing transaction or series of financing transactions of Borrower occurring
after January 22, 2016 but prior to the Maturity Date with aggregate net proceeds to Borrower of at least $2,000,000 pursuant to which Borrower issues any shares of the New Preferred, Common Stock and/or other equity securities of Borrower (the
“Next Financing”), Borrower shall repay to Lender $1,500,000, which payment shall be comprised of at least $300,000 in cash (with any greater cash amount determined by Borrower in its sole and absolute discretion), with the balance
of the $1,500,000 that is not paid in cash (the “Balance”) to be paid in the form of that number of fully paid and nonassessable shares of Borrower Equity as is equal to the quotient obtained by

 
dividing the Balance by the lesser of (a) the lowest per share price paid by investors in the Next Financing, and (b) $8.00 (as adjusted for any and all stock dividends, stock splits,
stock combinations or other similar transactions occurring after the date hereof), rounded down to the nearest whole share (the “Initial Payment”); provided, however, that if the number of shares of Borrower Equity to
be included in the Initial Payment, plus any shares of Common Stock that Lender beneficially owns as of immediately after the Next Financing, will, after giving effect to any shares of Common Stock issued in connection with the Next Financing and
the issuance of any shares of Common Stock included in the Initial Payment Amount, result in Lender beneficially owning in excess of 49.90% of Borrower’s outstanding Common Stock (the “Ownership Cap”), then the number of shares
of Borrower Equity included in the Initial Payment shall be reduced by a number of shares which results in Lender not exceeding the Ownership Cap, and the remaining amount of the Initial Payment shall be paid in cash. The Initial Payment shall be
applied, first, to accrued and unpaid interest on the Loans and, second, to the unpaid principal amount of the Loans. Each $1.00 of value of the Initial Payment shall reduce the amount of accrued and unpaid interest and then unpaid principal amount
on the Loans by $0.50.” 
 (ii) [Intentionally Omitted.]” 

3. Notice to Lender. Section 2(d)(i) of the Agreement shall be amended and restated to read in its entirety as follows: 

“(d) (i) [Intentionally Omitted.]” 

4. Stock Certificates. Section 2(d)(ii) of the Agreement shall be amended and restated to read in its entirety as follows: 

“(d) (ii) Stock Certificates. Borrower shall, as soon as practicable following consummation of the Next Financing where Borrower
is required to issue Borrower Securities, issue and deliver to Lender, or to its nominee or nominees, a certificate or certificates for the number of shares of Borrower Securities to which it shall be entitled as aforesaid. Such conversion shall be
deemed to have been made, as applicable, immediately prior to the close of business on the date of the closing of the Next Financing. The person or persons entitled to receive the Borrower Securities issuable upon such conversion shall be treated
for all purposes as the record holders of such Borrower Securities on such date.” 
 5. Optional Prepayment; Repayment.
Section 2(e) of the Agreement shall be amended and restated to read in its entirety as follows: 
 “(e) Optional Prepayment;
Repayment. 
 (i) Optional Prepayment in Part. In addition to the payment of cash and issuance of shares of Borrower Equity to
Lender in accordance with Section 2(c), Borrower may at any time after the Next Financing or from time to time after the Next Financing prepay any portion of the outstanding principal amount of the Loans, plus accrued and previously unpaid
interest thereon (each such portion, an “Additional Payment Amount”) by delivering to Lender a written notice specifying the Additional Payment Amount that Borrower elects to 

  
 2 

 
prepay (the “Additional Payment Notice”). Lender shall have a period of five (5) days following receipt of the Additional Payment Notice to elect, at its sole election and
discretion, by delivering an irrevocable writing delivered to Borrower (the “Lender Election Notice”), (a) to receive that number of fully paid and nonassessable shares of Borrower Equity as is equal to the quotient obtained by
dividing the Additional Payment Amount by the lesser of (1) (x) if the Additional Payment Notice is delivered to Lender within 180 days of the closing date of the Next Financing, the lowest per share price paid by investors in the Next
Financing, or (y) if the Additional Payment Notice is delivered to Lender 180 days or more after the closing date of the Next Financing, the volume weighted average closing price of the Common Stock, as reported by The Nasdaq Stock Market LLC,
for the thirty (30) consecutive trading days ending on the last trading date immediately preceding the date that the Additional Payment Notice is delivered to Lender, and (2) $8.00 (as adjusted for any and all stock dividends, stock
splits, stock combinations or other similar transactions occurring after the date hereof), rounded down to the nearest whole share, (b) to require Borrower to prepay the Additional Payment Amount in cash, or (c) to receive a combination of
shares under clause (a) and cash under clause (b) up to the aggregate value of the Additional Payment Amount. Notwithstanding the foregoing, if Lender does not deliver the Lender Election Notice to Borrower within five (5) days of
Lender’s receipt of the Additional Payment Notice with respect to an Additional Payment Amount, then the form of payment and mix of cash and Borrower Securities for such Additional Payment shall be at Borrower’s sole election and
discretion; provided, however, that if the number of shares of Borrower Equity to be included in an Additional Payment Amount, plus any shares of Common Stock that Lender beneficially owns as of immediately prior to the payment of the
Additional Payment Amount, will, after giving effect to the issuance of any shares of Common Stock included in the Additional Payment Amount, result in Lender beneficially owning shares of Common Stock in excess of the Ownership Cap, then the number
of shares of Borrower Equity included in such Additional Payment Amount shall be reduced by a number of shares which results in Lender not exceeding the Ownership Cap, and the remaining Additional Payment Amount shall be paid in cash. Each
additional payment made by Borrower to Lender pursuant to this Section 2(e)(i) (each, an “Additional Payment”) shall be applied, first, to accrued and unpaid interest on the Loans and, second, to the unpaid principal amount of
the Loan. Each $1.00 of value of each Additional Payment shall reduce the amount of accrued and unpaid interest and then unpaid principal amount on the Loans by $0.50. 

(ii) Repayment; Prepayment in Full. If: (a) the Loans are not fully repaid prior to the Maturity Date, the remaining Loans will
automatically mature and an amount equal to 200% of the aggregate of the principal amount of the Loans then outstanding and of all accrued and unpaid interest thereon (the “Remaining Balance”), shall be due and payable (or issuable
with respect to Borrower Securities) upon written demand by Lender, which demand may be made at any time on or after the Maturity Date, or (b) Borrower elects to prepay the remaining Loans in full prior to the Maturity Date, Borrower shall be
required to pay to Lender (or issue Borrower Securities) an amount equal to the Remaining Balance, as follows: (I) the issuance to Lender of such number of fully paid and nonassessable shares of Borrower Securities as is equal to the quotient
obtained by dividing the Remaining Balance by the lesser of (A) the volume weighted average closing price of the Common Stock, as reported by The Nasdaq Stock Market LLC, for the thirty (30) consecutive trading days ending on the last
trading date immediately preceding the date of Lender’s written demand for repayment or the date of 

  
 3 

 
Borrower’s prepayment in full, as applicable, and (B) $8.00 (as adjusted for any and all stock dividends, stock splits, stock combinations or other similar transactions occurring after
the date hereof), rounded down to the nearest whole share, (II) the entire Remaining Balance in cash, or (III) a combination of shares under clause (I) and cash under clause (II) up to the aggregate value of the Remaining Balance
(provided that Borrower may, at its sole election and discretion, elect to pay the entire Remaining Balance solely in cash and provided further, that if Borrower does not so elect to pay the entire Remaining Balance solely in
cash, the form of payment and mix of cash and Borrower Securities shall be at Lender’s sole election and discretion). 
 6. Interest
Rate. The reference to “five percent (5.0%)” in Section 2(f) of the Agreement shall be replaced with “two and a half percent (2.5%)”. 

7. Lock-Up Period. The first sentence of Section 13 of the Agreement shall be amended and restated to read in its entirety as
follows: 
 “The original Lender hereby agrees that it shall not, prior to January 23, 2017 (the “Lock-Up
Period”), directly or indirectly, sell or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock then or thereafter owned either of record or
beneficially (as defined in the Securities Exchange Act of 1934, as amended) by the original Lender.” 
 8. Each of the following
defined terms and definitions set forth in Schedule A to the Agreement shall be deleted: “Equity Financing”; “Qualified Follow-on Public Offering” and “Qualified Private Financing”. 

9. All of the other provisions of the Agreement shall remain in full force and effect. 

10. This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, and all of
which taken together shall constitute one and the same agreement. In the event that any signature is delivered by facsimile, a portable document format (PDF) or similar electronic format, such signature shall create a valid binding obligation of the
party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile, PDF or other electronic format signature were the original thereof. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have caused this Second Amendment to Loan and Security
Agreement to be duly executed on the day and year first above written. 
  

			
	BORROWER:
	
	VIKING THERAPEUTICS, INC.
		
	By:	 	 /s/ Brian Lian, Ph.D.

	Name:	 	Brian Lian, Ph.D.
	Title:	 	President and Chief Executive Officer
	
	LENDER:
	
	LIGAND PHARMACEUTICALS INCORPORATED
		
	By:	 	 /s/ Charles Berkman

	Name:	 	Charles Berkman
	Title:	 	VP, General Counsel & Secretary

 [Signature Page to Second Amendment to Loan and Security Agreement]EX-10.2

 Exhibit 10.2 

EXECUTION VERSION 
 VIKING
THERAPEUTICS, INC. 
 FIRST AMENDMENT TO REGISTRATION RIGHTS AGREEMENT 

THIS FIRST AMENDMENT TO REGISTRATION RIGHTS
AGREEMENT (this “Amendment”) is dated as of January 22, 2016 by and between Viking Therapeutics, Inc., a Delaware corporation (the “Company”), and Ligand
Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”). 
 RECITALS 

WHEREAS, the Company, Ligand and Metabasis Therapeutics, Inc., a Delaware corporation, are parties to
that certain Registration Rights Agreement, dated as of May 21, 2014 (the “Original Agreement”); 

WHEREAS, the Company and Ligand desire to amend the Original Agreement as set forth herein; and 

WHEREAS, Section 3.1 of the Original Agreement provides, among other things, that no provision of
the Original Agreement may be modified or amended except by a written agreement specifically referring to the Original Agreement and signed by the Company and Ligand, and any such amendment effected in accordance with Section 3.1 of the
Original Agreement will be binding upon each Holder and each future holder of all such securities of such Holder. 
 NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants and conditions set forth below, and in reliance on the recitals set forth above, and for other good and valuable consideration, the
receipt of which is hereby acknowledged, the parties to this Amendment hereby agree as follows:  
 ARTICLE 1 

AMENDMENTS 
 1.1
Amendment and Restatement of Section 1.1(y) of the Original Agreement. Section 1.1(y) of the Original Agreement is hereby amended and restated in its entirety as set forth below: 

“(y) “Lock-up Expiration Date” shall mean January 23, 2017.” 

ARTICLE 2 
 GENERAL
PROVISIONS 
 2.1 Capitalized Terms. All capitalized terms used in this Amendment, to the extent not otherwise defined herein, shall
have the meanings assigned to them in the Original Agreement. 
 2.2 Continuing Effectiveness. Except as modified by this Amendment,
the Original Agreement shall remain in full force and effect and no party by virtue of entering into this Amendment is waiving any rights it has under the Original Agreement, and once this 

 
Amendment is executed by the parties hereto, all references in the Original Agreement to “the Agreement” or “this Agreement,” as applicable, shall refer to the Original
Agreement as modified by this Amendment. 
 2.3 Governing Law. This Amendment, and the relations of the parties hereto, shall be
governed by and interpreted in accordance with the laws of the State of California, excluding application of any conflict of laws principles that would require application of the law of a jurisdiction outside of California, and will be subject to
the exclusive jurisdiction of the courts of competent jurisdiction located in San Diego County, California. 
 2.4 Counterparts. This
Amendment may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A facsimile or a portable document format (PDF) copy of this Amendment, including the
signature pages, will be deemed an original. 
 2.5 Entire Agreement. This Amendment constitutes and contains the entire
understanding and agreement of the parties respecting the subject matter hereof and cancels and supersedes any and all prior or contemporaneous negotiations, correspondence, understandings and agreements between or among the parties, whether oral or
written, regarding such subject matter (provided, that any and all previous nondisclosure/nonuse obligations are not superseded and remain in full force and effect). 

[Signature Page Follows] 

  
 2 

 IN WITNESS WHEREOF, the
parties have executed this First Amendment to Registration Rights Agreement as of the date first above written. 
  

			
	THE COMPANY:
	
	 VIKING THERAPEUTICS, INC.,

a Delaware corporation

		
	By:	 	 /s/ Brian Lian, Ph.D.

	Name:	 	Brian Lian, Ph.D.
	Title:	 	President and Chief Executive Officer
	
	LIGAND:
	
	 LIGAND PHARMACEUTICALS INCORPORATED,

a Delaware corporation

		
	By:	 	 /s/ Charles Berkman

	Name:	 	Charles Berkman
	Title:	 	VP, General Counsel & Secretary

 [Signature Page to First Amendment to Registration Rights Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]